Pay-for-delay deals declining, FTC report says

There have been more patent settlements involving generic drugs but fewer of them included provisions containing reverse payments, according to a Federal Trade Commission staff report....

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:

FTCWatch is delivered in the following formats: via email alert and online at